Pfizer Stock Drops Despite Market Gains; Q3 Earnings and Revenue Expected to Decline
• Pfizer (PFE) stock dropped 0.32% despite market gains; trailed the S&P 500, Dow, and Nasdaq • Pfizer expected to report 54.47% drop in Q3 2022 EPS ($0.56) and 22.32% decline in revenue ($14.2B) • For full year 2022, consensus estimates call for +20.11% jump in EPS ($2.21) and +2.61% revenue growth ($60.03B) • Pfizer has Zacks Rank #3 (Hold); valuation metrics show stock trading at discount to industry • Pfizer part of Large Cap Pharmaceuticals industry group ranked in bottom 18% by Zacks (underperforming market)